Arthur Dyer

R&D, AstraZeneca
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Characterisation of human in vitro tumour-associated macrophage models to define translational relevance.

Characterisation of human in vitro tumour-associated macrophage models to define translational relevance.

Journal: Scientific reports
Published: May 01, 2025

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.

Journal: Journal for immunotherapy of cancer
Published: March 10, 2021

The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy.

The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy.

Journal: Cytokine & growth factor reviews
Published: June 22, 2020

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.

Journal: Cancers
Published: February 15, 2020

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.

Journal: Journal for immunotherapy of cancer
Published: June 12, 2019

Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.

Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.

Journal: Cancer research
Published: May 09, 2018

Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference.

Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference.

Journal: Cancer gene therapy
Published: May 01, 2018

Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer.

Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer.

Journal: Virology
Published: November 04, 2016

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.

Journal: Molecular therapy oncolytics
Published: July 19, 2016
Showing 1-9 of 9

Last Updated: 09/26/2026